Selective Inhibition of PI3K Isoforms in Brain Tumors Suppresses Tumor Growth by Increasing Radiosensitivity

Combining radiation with PI3K isoform-selective inhibitor administration increases radiosensitivity and suppresses tumor growth in non-small cell lung cancer

(2022) Mi Youn Seol et al.   JOURNAL OF RADIATION RESEARCH

PI3k inhibitors (BKM120 and BYL719) as radiosensitizers for head and neck squamous cell carcinoma during radiotherapy

(2021) Fu-Cheng Chuang et al.   PLoS One

First-in-human Phase I study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma

(2020) Patrick Y. Wen et al.   CLINICAL CANCER RESEARCH

Radioresistance in Glioblastoma and the Development of Radiosensitizers

(2020) Md Yousuf Ali et al.   Cancers

Behaviors of Glioblastoma Cells in in Vitro Microenvironments

(2019) Wenwen Diao et al.   Scientific Reports

Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors

(2019) Ying Zhang et al.   Expert Opinion on Drug Metabolism & Toxicology

Management of toxicity to isoform α-specific PI3K inhibitors

(2019) S E Nunnery et al.   ANNALS OF ONCOLOGY

Clinically relevant radioresistant cell line: a simple model to understand cancer radioresistance

(2017) Yoshikazu Kuwahara et al.   Medical Molecular Morphology

Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development

(2017) Hua-fu Zhao et al.   Molecular Cancer

Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma

(2017) Aviram Mizrachi et al.   Nature Communications

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

(2016) Cristian Massacesi et al.   OncoTargets and Therapy

Novel agents and associated toxicities of inhibitors of the pi3k/Akt/mtor pathway for the treatment of breast cancer

(2015) S. Chia et al.   Current Oncology

A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma

(2015) Manfred Westphal et al.   EUROPEAN JOURNAL OF CANCER

Molecules in medicine mini-review: isoforms of PI3K in biology and disease

(2015) Bart Vanhaesebroeck et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

The PI3K/AKT/mTOR interactive pathway

(2015) Tulin Ersahin et al.   Molecular BioSystems

The Brain Microenvironment Preferentially Enhances the Radioresistance of CD133+ Glioblastoma Stem-like Cells

(2015) Muhammad Jamal et al.   NEOPLASIA

DNA double-strand break repair pathway choice and cancer

(2014) Tomas Aparicio et al.   DNA REPAIR

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

(2014) Roger Stupp et al.   LANCET ONCOLOGY

PI3K and cancer: lessons, challenges and opportunities

(2014) David A. Fruman et al.   NATURE REVIEWS DRUG DISCOVERY

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of PI3K inhibitors: lessons learned from early clinical trials

(2013) Jordi Rodon et al.   Nature Reviews Clinical Oncology

Ionizing-radiation induced DNA double-strand breaks: A direct and indirect lighting up

(2013) Julien Vignard et al.   RADIOTHERAPY AND ONCOLOGY

mTORC1 Inhibition Is Required for Sensitivity to PI3K p110  Inhibitors in PIK3CA-Mutant Breast Cancer

(2013) M. Elkabets et al.   Science Translational Medicine

Targeting the Akt-pathway to Improve Radiosensitivity in Glioblastoma

(2012) Ravi S. Narayan et al.   CURRENT PHARMACEUTICAL DESIGN

PI3K: A potential therapeutic target for cancer

(2011) Yingwei Chen et al.   JOURNAL OF CELLULAR PHYSIOLOGY

EGFRvIII and DNA Double-Strand Break Repair: A Molecular Mechanism for Radioresistance in Glioblastoma

(2009) B. Mukherjee et al.   CANCER RESEARCH

Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells

(2009) Hui-Fang Li et al.   Radiation Oncology

Class I PI3 Kinase Inhibition by the Pyridinylfuranopyrimidine Inhibitor PI-103 Enhances Tumor Radiosensitivity

(2008) R. Prevo et al.   CANCER RESEARCH

Epidermal growth factor receptor and glioblastoma multiforme: molecular basis for a new approach

(2008) Cristóbal Belda-Iniesta et al.   Clinical & Translational Oncology

Targeting the PI3K p110  Isoform Inhibits Medulloblastoma Proliferation, Chemoresistance, and Migration

(2008) A. S. Guerreiro et al.   CLINICAL CANCER RESEARCH

Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis

(2008) Shidong Jia et al.   NATURE